In the later phases of cancer progression, TGF-β signaling can reduce expression of epithelial markers, such as E-cadherin, and promote epithelial-to-mesenchymal transition (EMT) by increasing the expression of mesenchymal markers including N-cadherin and vimentin [27, 28]. The gene discussed is CDH2; the disease is cancer.